coalit
public
health
expert
doctor
scientist
worldwid
want
draw
attent
need
highqual
evalu
protocol
potenti
benefici
effect
hydroxychloroquin
hcq
postexposur
drug
expos
peopl
mean
peopl
close
contact
posit
test
patient
includ
home
medic
caregiv
review
mechan
antivir
effect
hcq
riskbenefit
ratio
take
consider
pkpd
hcq
threshold
efficaci
studi
use
antimalari
antivir
immunomodul
drug
conclud
use
hcq
match
standard
treatment
system
lupu
erythemat
proven
safeti
efficaci
term
hcq
blood
tissu
concentr
adapt
bodyweight
load
dose
follow
mgkgday
maximum
limit
mgday
case
swiftli
clinic
evalu
postexposur
drug
expos
peopl
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
epidem
howev
administr
done
medic
control
avo
id
potenti
side
effect
prevent
uncontrol
use
lead
suppli
shortag
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
journal
preproof
world
face
signific
challeng
briefli
includ
prevent
diseas
treat
sever
case
reduc
medic
social
econom
impact
ill
end
pandem
social
distanc
measur
rapidli
implement
albeit
uniformli
known
public
health
measur
contact
trace
also
variabl
implement
clinic
trial
underway
use
repurpos
drug
new
drug
new
technolog
develop
antibodi
drug
review
recent
share
preliminari
result
reveal
data
valuabl
fail
provid
definit
evid
effect
lead
compound
mainli
initi
studi
observ
control
studi
thu
document
treatment
still
lack
spite
pauciti
clinic
evid
unequivoc
benefici
effect
chloroquin
absenc
effect
treatment
far
untim
public
given
j
u
r
n
l
p
r
e
p
r
f
potenti
effect
chloroquin
consequ
social
polit
pressur
rais
demand
urgent
clinic
trial
even
result
simultan
releas
drug
compassion
use
treatment
sever
case
meanwhil
develop
safe
effect
vaccin
like
take
mani
month
year
crucial
issu
yet
adequ
address
pharmacolog
control
viru
replic
contact
case
individu
show
symptom
use
drug
potenti
reduc
risk
diseas
manifest
decreas
presymptomat
spread
consid
incred
amount
conflict
medic
polit
social
debat
alway
scientif
base
use
drug
treatment
time
implement
prospect
clinic
trial
answer
question
prophylact
dose
hydroxychloroquin
decreas
risk
clinic
infect
document
expos
peopl
consid
ongo
world
tragedi
option
discard
even
robust
scientif
evid
still
lack
want
draw
attent
need
highqual
evalu
protocol
potenti
benefici
effect
hydroxychloroquin
hcq
postexposur
drug
expos
peopl
mean
peopl
close
contact
posit
test
patient
includ
home
medic
caregiv
provid
inform
justifi
clinic
trial
hydroxychloroquin
postexposur
drug
togeth
background
need
safe
properli
design
clinic
trial
take
consider
pkpd
hydroxychloroquin
action
viru
includ
coronavirida
potenti
toxic
human
impact
repurpos
patient
inflammatori
diseas
hydroxychloroquin
exposur
million
peopl
current
expos
high
risk
contamin
among
adult
take
care
famili
member
test
posit
home
medic
paramed
staff
treat
hospit
patient
symptomat
highli
suscept
infect
may
repres
second
wave
extrem
import
next
week
peopl
get
sick
face
anoth
signific
problem
highli
expos
peopl
protect
case
j
u
r
n
l
p
r
e
p
r
f
social
distanc
measur
appli
absenc
vaccin
postexposur
pharmacolog
protect
way
prevent
caregiv
becom
symptomat
promot
gener
use
hcq
prophylaxi
gener
popul
four
main
reason
evid
hcq
may
kill
viru
vitro
yet
data
regard
use
hcq
postexposur
asymptomat
peopl
recommend
favor
uncontrol
use
hcq
lead
risk
inappropri
use
could
caus
seriou
side
effect
inefficaci
suppli
shortag
nonauthor
specul
design
prospect
clinic
trial
test
gener
use
would
difficult
challeng
establish
control
popul
unexpos
person
lead
difficulti
data
analysi
lack
evid
risk
sideeffect
requir
close
followup
clinic
monitor
recommend
postexposur
regimen
hcq
asymptomat
peopl
whether
test
close
contact
symptomat
patient
posit
start
regimen
soon
possibl
hcq
blood
concentr
reach
steadyst
take
time
approxim
six
day
incub
period
symptom
also
approxim
six
day
thu
regimen
start
first
day
exposur
risk
promot
use
hcq
match
standard
treatment
system
lupu
erythemat
proven
safeti
efficaci
term
hcq
blood
tissu
conc
ntration
adapt
bodyweight
load
dose
follow
mgkgday
maximum
limit
mgday
case
durat
postexposur
regimen
last
long
contact
posit
patient
last
case
repeat
exposur
minimum
day
reach
blood
concentr
steadi
state
termin
elimin
halflif
approxim
day
lead
long
term
efficaci
consid
highli
document
safeti
oral
administ
hcq
short
time
consid
highest
possibl
dose
use
control
compet
medic
staff
order
reach
minimum
hcq
tissu
level
requir
inactiv
clinic
signific
proport
viru
hydroxychloroquin
solubl
hydroxyanalogu
chloroquin
cq
first
synthes
han
andersag
proven
militari
test
world
war
ii
safe
antimalari
use
success
centuri
prevent
treat
malaria
endem
area
studi
reveal
hydroxychloroquin
hcq
immunomodulatori
properti
lead
use
treatment
autoimmun
diseas
lupu
rheumatoid
arthriti
earli
research
note
antivir
effect
hydroxychloroquin
current
refer
pubm
obtain
use
keyword
viru
hydroxychloroquin
similarli
web
scienc
reveal
high
interest
hydroxychloroquin
role
viral
diseas
sinc
earli
hydroxychloroquin
chloroquin
demonstr
vitro
antivir
effect
herp
simplex
viru
type
zika
hiv
mer
sarscov
chikungunya
hepat
c
sever
virus
coronaviru
studi
suggest
least
vitro
efficaci
chloroquin
sarscov
viru
merscov
use
vero
cell
infect
wang
et
al
conduct
standard
assay
determin
potenc
halfmaxim
effect
concentr
ec
cytotox
halfmaxim
cytotox
concentr
cc
chloroquin
wang
studi
show
cq
potenc
ec
great
safeti
therapeut
dose
sinc
cq
show
signific
toxic
concentr
exceed
cc
greater
previou
studi
show
cq
ic
cc
recent
yao
et
al
show
hydroxychloroquin
hcq
potent
chloroquin
ec
ec
respect
hour
hydroxychloroquin
show
high
partit
tissu
includ
lung
brain
chemic
properti
offer
key
clinic
advantag
case
hcq
tenfold
concentr
ratio
lung
recent
review
describ
seri
case
report
children
present
interstiti
lung
diseas
treat
hcq
cq
dose
rang
mgkg
bodi
weightday
maximum
mgday
hcq
welltoler
case
rel
side
effect
patient
treat
exclus
hcq
cq
symptom
improv
case
sign
anosmia
hyposmia
common
coronavirus
current
loss
smell
note
mani
patient
even
otherwis
asymptomat
wwwentukorgsitesdefaultfilesfileslossofsenseofsmellasmarkerofcovid
sign
like
aris
consequ
pass
olfactori
epithelium
olfactori
area
brain
concept
support
studi
coronavirus
previou
work
indic
could
cross
cribriform
plate
ethmoid
bone
produc
cerebr
involv
hydroxychloroquin
penetr
central
nervou
system
patient
glioblastoma
safe
treat
hcq
use
conjunct
radiat
adjuv
correl
brain
plasma
concentr
show
differ
hcq
demonstr
abil
diffus
brain
base
observ
hydroxychloroquin
may
reach
antivir
concentr
brain
lead
expect
prevent
effect
earli
symptom
anosmia
may
persist
recoveri
hydroxychloroquin
wide
rang
indic
includ
rheumatoid
arthriti
system
lupu
erythematosu
polymorph
light
erupt
physician
desk
refer
hydroxychloroquin
sulfat
drug
summari
http
wwwpdrnetdrugsummaryplaquenil
access
march
hcq
administ
oral
dose
rang
mg
daili
hcq
also
test
indic
cancer
multipl
sclerosi
diabet
mellitu
current
context
extrem
worldwid
emerg
reason
propos
even
could
reduc
viru
replic
would
like
significantli
reduc
transmiss
sever
improv
clinic
outcom
use
describ
propos
threshold
efficaci
valu
exceed
valu
specif
describ
drug
could
decreas
viru
replic
viral
surviv
j
u
r
n
l
p
r
e
p
r
f
base
propos
lower
plasma
concentr
hcq
easili
obtain
standard
dosag
regimen
like
signific
clinic
public
health
impact
antivir
activ
hcq
thu
demonstr
higher
cytotox
side
effect
permit
high
select
index
current
cq
hcq
denigr
potenti
side
effect
toxic
describ
featur
transient
high
danger
peak
concentr
may
develop
parenter
appropri
oral
administr
risk
retinopathi
associ
hydroxychloroquin
treatment
well
document
decad
recent
shown
preval
retinopathi
rang
patient
treat
year
need
use
hcq
extend
period
postexposur
medic
risk
cardiomyopathi
includ
cardiac
conduct
disord
reduc
drug
regimen
howev
recommend
ecg
initi
treatment
case
cardiac
anteced
delay
start
postexposur
regimen
evid
lack
signific
risk
retin
toxic
exposur
hcq
utero
consid
lack
evid
safeti
postexposur
hydroxychloroquin
pregnanc
consid
pregnant
women
exclud
futur
clinic
trial
exact
mechan
action
chloroquin
hydroxychloroquin
viru
clearli
depict
howev
laboratori
data
show
compound
chloroquin
hydroxychloroquin
four
mechan
act
divers
rna
virus
includ
reduc
cytokin
storm
virus
gener
drug
also
reduc
express
helper
tcell
essenti
success
antibodi
respons
class
switch
immunomodulatori
action
could
help
prevent
transit
mild
moder
diseas
dread
acut
respiratori
distress
syndrom
reduc
cytokin
storm
nonpharmaceut
measur
social
distanc
school
closur
telework
di
domenico
et
al
expect
impact
school
closur
telework
mitig
epidem
franc
report
march
epicxlabcom
http
expect
delay
reduc
peak
incid
achiev
reduct
final
attack
rate
addit
epicxlab
report
reason
intervent
lead
signific
reduct
impact
epidem
profil
consid
evalu
without
delay
observ
logarithm
increas
number
case
death
well
social
econom
impact
measur
prevent
mean
control
outbreak
becom
urgent
use
hydroxychloroquin
postexposur
mean
reduc
sick
transmiss
demand
immedi
attent
taken
consider
utmost
import
promot
design
prospect
clini
cal
trial
test
hypothesi
postexposur
nontox
dose
hydroxychloroquin
significantli
alter
replic
peopl
expos
document
infect
contact
reduc
sever
subsequ
diseas
futur
clinic
trial
document
benefitrisk
ratio
strategi
rapidli
strategi
prevent
clearli
achiev
consid
safeti
hydroxychloroquin
short
period
time
demonstr
antivir
effect
low
cost
access
context
epidem
clinic
evid
prospect
control
clinic
trial
confirm
posit
impact
implement
urgent
need
suppli
shortag
hydroxychloroquin
remain
need
standard
indic
lupu
rheumatoid
arthriti
prevent
signific
effort
pharmaceut
compani
alreadi
ongo
increas
product
hydroxychloroquin
specif
initi
defens
product
act
us
may
activ
use
postexposur
hcq
line
strateg
object
limit
humantohuman
transmiss
serious
consid
use
easi
safe
option
take
risk
allow
pandem
sore
control
recent
state
urgenc
epidem
necessit
choic
intervent
employ
earli
hcq
administr
peopl
risk
infect
close
contact
posit
patient
one
reason
choic
moreov
choic
could
potenti
consider
impact
earli
termin
